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A case of giant cell myocarditis: Bridge to recovery by long-term
mechanical circulatory support without immunosuppressive therapy
Toshifumi Murashita, MD, PhD, Takashi Sugiki, MD, Tsuyoshi Tachibana, MD, PhD, Takashi Kunihara, MD, PhD,
and Hiroshi Sugiki, MD, Sapporo, Japan
Giant cell myocarditis (GCM) is an uncommon andrapidly fatal disorder resulting in cardiac transplanta-tion or death.1 Immunosuppressive therapy could pro-long the average transplant-free survival period of
patients GCM. The ventricular-assist device (VAD) usually pro-
vides support during the period of assessment of transplant candi-
dacy, and there is only 1 reported case of a bridge to recovery with
immunosuppression.2 We report the unusual case of a young
patient with cardiogenic shock caused by GCM who recovered
after 7 months of left ventricular assistance without immunosup-
pressive therapy.
Clinical Summary
A 28-year-old woman (158 cm, 39 kg) had been experiencing
progressive symptoms, including fatigue and dyspnea. An electro-
cardiogram showed complete heart block, and an echocardiogram
showed a left ventricular ejection fraction (LVEF) of 0.17 with a
dilated left ventricle. Despite support with intra-aortic balloon
pumping and percutaneous cardiopulmonary support, the lack of
improvement of left ventricular function led to the need for a left
VAD. The left VAD (Toyobo VAD; Toyobo Ltd, Osaka, Japan) was
placed by using a cannula with a graft extension sewn onto the aorta
as the outflow line, while the inflow line was inserted through the left
ventricular apex and the muscle excised from the apex was sent for
examination. Histologic examination (Figure 1) indicated GCM.
After the operation, maximum inotropic support was required
because of right ventricular failure. Although the literature sug-
gests a beneficial effect of immunosuppression for GCM, this was
kept in reserve because of possible infection in the situation of left
VAD implantation. A right ventricular catheter biopsy carried out
on the 62nd postoperative day showed a mixed inflammatory
infiltrate without giant cells. During this period, brain natriuretic
peptide was decreased from 1176 pg/mL to 232 pg/mL, whereas
echocardiography showed improved left ventricular function with
LVEF of 0.25. Carvedilol, a -blocker, was commenced and
increased stepwise, during which time brain natriuretic peptide
was further decreased to 48 pg/mL. Repeated right ventricular
biopsy showed fewer inflammatory cells and increased fibrosis but
no giant cells, whereas left ventricular function was further im-
proved with LVEF of 0.45 in a left VAD off test. The patient was
successfully weaned from the left VAD on the 222nd postopera-
tive day. The patient’s condition has been good without immuno-
suppression for 1 year. Recent echocardiography revealed LVEF
of 0.47. The patient is in New York Heart Association functional
class I, and she has returned to normal life.
Discussion
A report that analyzed data in the Multicenter Giant Cell Myocar-
ditis Registry found ventricular assistance to be an effective bridge
to transplantation for patients with GCM-induced heart failure.3
The success rate of bridging patients with GCM to transplantation
with a VAD, 78%, is similar to that with other VAD bridges;
however, no patient was weaned from the VAD. Another recent
study suggests that the average transplant-free survival period of
patients with GCM treated with immunosuppression is more than
4 times longer than that of patients who receive no immunosup-
pressive therapy. There was 1 reported case of a bridge to recovery
for GCM; in that case, the recovery with immunosuppression was
sufficient to obviate the need for heart transplantation, and the
patient was weaned from the VAD after 10 days of assistance.2
Acute myocarditis caused by GCM is rare, not all patients
undergo endomyocardial biopsy for histologic diagnosis, and the
timing of the biopsy varies. Because the diagnosis of GCM can be
made when histologic findings are confirmed, regardless of the
timing of the biopsy, the incidence of GCM among patients with
myocarditis is uncertain. In our case, diagnosis of GCM was made
with left ventricular muscle taken from the left ventricular apex in
the acute phase, whereas the postoperative repeated endomyocar-
dial biopsy was performed on the right ventricle, which may differ
from the left. Because the complex inflammatory and healing
processes are difficult to characterize with a snapshot of tissue
pathology, serial endomyocardial biopsies are required.4
Another group5 reported a patient with GCM who had been in
cardiogenic shock but recovered completely after conventional
immunosuppression. They inferred that GCM is a heterogeneous
disease, with one form that can recover with immunosuppressive
therapy and another form that cannot recover and requires cardiac
transplantation. Because it is detected earlier, a rapidly progressive
acute inflammatory disease may be less damaging than a slowly
progressive one, provided that circulatory support is begun in time.
It is quite possible that chronic inflammatory changes greatly
reduce the potential for recovery from a slowly progressive dis-
ease. One may hypothesize from this case that GCM is a hetero-
geneous disease with one form that can recover without immuno-
suppression and other forms that respond to immunosuppressive
therapy or require cardiac transplantation.
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Ascending–descending aortic bypass with the aid of
a heart-lifting device
Alejandro Aris, MD, PhD,a Javier Cobiella, MD,a Maria Luz Maestre, MD,b and
Maria Teresa Subirana, MD,c Barcelona, Spain
Extra-anatomic aortic bypass from the ascending to thedescending aorta is an alternative for repair of complexaortic anomalies. We describe a case of repair of reco-arctation of the aorta through a median sternotomy and
posterior pericardial approach in which surgical exposure of the
retrocardiac aorta was ob-
tained by means of a heart-
lifting device (Starfish 2;
Medtronic, Inc, Minneapolis, Minn) commonly used in off-pump
coronary artery bypass grafting.
Clinical Summary
A 70-year-old man was seen with dyspnea on exertion and intermit-
tent claudication. He was hypertensive, in atrial fibrillation, and taking
oral anticoagulants. His medical history included repair of aortic
coarctation (end-to-end anastomosis) 29 years previously. Echocardi-
ography showed left ventricular hypertrophy with moderately de-
pressed left ventricular function (ejection fraction 40%). He under-
went aortic angiography, which confirmed the diagnosis of aortic
recoarctation with a gradient of 48 mm Hg across the coarctation. The
thoracic descending aorta was tortuous (Figure 1).
In view of the patient’s age and left ventricular impairment, it
was decided that an extra-anatomic repair would be less harmful
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Figure 1. A, Histologic examination showing widespread or multifocal serpiginous necrosis with multinucleated
giant cells and mixed inflammatory infiltrate composed of lymphocytes and few eosinophils. B, Multinucleated
giant cells seen adjacent to necrosis.
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